Ranibizumab

Ranibizumab is a prescription medication specifically designed to treat certain eye disorders, such as neovascular age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and diabetic macular edema. It is a biologic drug, which means it is derived from living organisms, in this case, a monoclonal antibody that targets a specific protein called vascular endothelial growth factor (VEGF).
VEGF is a key factor in the growth of new blood vessels in the eye, which can lead to vision loss in conditions like AMD. By inhibiting the action of VEGF, Ranibizumab helps to stabilize vision and, in some cases, improve visual acuity.
Ranibizumab is administered through a series of intravitreal injections, which means the medication is directly injected into the vitreous humor of the eye under sterile conditions. The number of injections required and the interval between them can vary depending on the patient’s individual response to treatment and the specific condition being treated.
Ranibizumab should only be prescribed by a qualified healthcare professional, such as an ophthalmologist, who will closely monitor the patient’s progress and make any necessary adjustments to the treatment plan. The medication is intended for use in conjunction with other supportive measures, including regular eye examinations and lifestyle modifications, to ensure the best possible outcome.